PDE4 Inhibition in Seborrheic Dermatitis and Papulopustular Rosacea
This study is a double-blind, vehicle-controlled clinical trial. The study will take place at Icahn School of Medicine at Mount Sinai. The study will include 33-39 adult subjects with moderate-to-severe-Seborrheic dermatitis (SD) as well as 33-39 adult subjects with mod...
Age: 18 years - 66+
Gender: All
Ruxolitinib in Seborrheic Dermatitis
This study is an open-label prospective interventional trial that will assess the efficacy of
ruxolitinib in the treatment of seborrheic dermatitis. It will also attempt to characterize
the molecular immune profiles of patients with SD at week 0 and week 4, with com...
Age: 18 years - 66+
Gender: All
A Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon)
The co-primary objectives of the study are to:
- Evaluate the efficacy of rocatinlimab compared with placebo at Week 24, assessed using
Validated Investigator's Global Assessment for Atopic Dermatitis (vIGA-AD).
- Evaluate the efficacy of rocatinlimab compared...
Age: 18 - 100 years
Gender: All
A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)
The primary objective of this study is to describe the safety and tolerability of
rocatinlimab in adolescents with moderate-to-severe AD.
Age: 12 - 17 years
Gender: All
Longitudinal Endotyping Of Atopic Dermatitis Through Transcriptomic Skin Analysis
This is a multi-center, longitudinal study which will characterize the gene expression
profiles and transcriptomic endotypes that underlie mild and moderate-severe Atopic
dermatitis (AD) and will determine changes in these expression patterns and endotypes in
resp...
Age: 6 years - 66+
Gender: All
An Efficacy and Safety Study of RPT193 in Adults With Atopic Dermatitis
Phase 2 study of RPT193 in adults with atopic dermatitis
Age: 18 - 75 years
Gender: All
JAK Inhibition in Food Allergy
This study will assess the role for an oral targeted medication, abrocitinib, as a new
treatment option for food allergy patients that would avoid injections. Abrocitinib, which
has successfully completed phase three trials for atopic dermatitis, could serve as a si...
Age: 18 - 50 years
Gender: All
Systems Biology of Early Atopy
The goal of this study is to establish a birth cohort that collects prenatal and early life
biosamples and environmental samples and rigorously phenotypes young children for food
allergy and Atopic Dermatitis (AD) to identify prenatal and early life markers of high ...
Age: 0 years - 66+
Gender: All
Defining the Skin and Blood Biomarkers of Pediatric Atopic Dermatitis
Atopic dermatitis (AD), also known as eczema, is the most common inflammatory skin disorder
of children, affecting 10-20% of children and 1-2% of adults.
This skin disorder can be associated with unbearable itchiness and an increased
susceptibility to skin infec...
Age: 0 months - 17 years
Gender: All